BNGO - CIK 0001411690
Bionano Genomics, Inc. trades as BNGO. In its fiscal 2025 annual report the company posted revenue of $28.51M, down 7.4% from the prior year and net income of -$26.39M. This page tracks Bionano Genomics, Inc. through 603 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 8 fiscal years Bionano Genomics, Inc.'s revenue grew from $9.51M to $28.51M, a compound annual growth rate of 14.7%. Net profit margin expanded from -245.8% to -92.6% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-28 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-13 |
The largest companies sharing Bionano Genomics, Inc.'s SEC industry classification (laboratory analytical instruments).
Bionano Genomics, Inc. reported revenue of $28.51M for fiscal year 2025, a decrease of 7.4% year over year.
In its latest fiscal year Bionano Genomics, Inc. reported a net loss of $26.39M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.